Emerging Roles of SPINK1 in Cancer
- 1 March 2016
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 62 (3) , 449-457
Abstract
BACKGROUND: Tumor-associated trypsin inhibitor (TATI) was originally isolated from the urine of a patient with ovarian cancer. It was later shown to be produced by many other tumors and several normal tissues. It had earlier been isolated from the pancreas and was hence called pancreatic secretory trypsin inhibitor (PSTI). It belongs to a family of protease inhibitors presently called serine peptidase inhibitor Kazal type (SPINK). In the SPINK family TATI/PSTI is SPINK1, which is the name used in this review.CONTENT: In addition to being a protease inhibitor, SPINK1 also acts as an acute-phase reactant and a growth factor. Furthermore, it has been shown to modulate apoptosis. Overexpression of SPINK1 predicts an unfavorable outcome in several cancers and determination of SPINK1 in serum can be used to identify patients at increased risk of aggressive disease. Thus serum SPINK1 can be used as a prognostic tumor marker. Because SPINK1 acts as a growth factor and an inhibitor of apoptosis in some cancers, it has also been suggested that it can be a therapeutic target in cancer. However, because SPINK1 is the major physiological inhibitor of trypsin, inhibition of SPINK1 may increase the risk of pancreatitis.SUMMARY: Taking into account the many functions of SPINK1, assessing the role of SPINK1 in cancer has several potentially important clinical applications ranging from a biomarker to a potential new target for cancer therapy.Keywords
Funding Information
- Research Council of Finland (263755, 135937)
- Sigrid Juséliuksen Säätiö
This publication has 75 references indexed in Scilit:
- Concomitant Tumor Expression of EGFR and TATI/SPINK1 Associates with Better Prognosis in Colorectal CancerPLOS ONE, 2013
- Global Gene Expression Profiling Reveals SPINK1 as a Potential Hepatocellular Carcinoma MarkerPLOS ONE, 2013
- Role of the inflammatory protein serine protease inhibitor Kazal in preventing cytolytic granule granzyme A-mediated apoptosisImmunology, 2011
- Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancerEMBO Molecular Medicine, 2011
- Therapeutic Targeting of SPINK1-Positive Prostate CancerScience Translational Medicine, 2011
- Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patientsBMC Cancer, 2010
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature, 2010
- High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancerBritish Journal of Cancer, 2009
- Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissuesGenome Biology, 2008
- The Role of SPINK1 in ETS Rearrangement-Negative Prostate CancersCancer Cell, 2008